A panel of the Ninth Circuit on Friday denied a request by Valeant Pharmaceuticals for a review of its decision to revive a False Claims Act. The Act has accused Valeant of fraudulently procuring a patent in an effort to extend its monopoly on the drug Apriso. Valeant Pharmaceuticals, a major drug manufacturer, had hoped for a different outcome but the Ninth Circuit judges chose to stand by their original ruling.
The exact implications and reasons for the denial of the review are locked behind a subscriber’s access but the information available is from an article as reported by Law360, a trusted source for legal news and analysis.
This ongoing dispute raises further questions about the practices and procedures employed by pharmaceutical companies when securing exclusive rights for their products.